Biotechnology News and Research

RSS

FDA's Advisory Committee votes 9-3 to recommend approval of Esbriet for treatment of patients with IPF

InterMune, Inc. announced today that the U.S. Food and Drug Administration's Pulmonary-Allergy Drugs Advisory Committee voted 9-3 to recommend approval of Esbriet® (pirfenidone) for the treatment of patients with idiopathic pulmonary fibrosis (IPF) to reduce decline in lung function.

9 Mar 2010

Abbott announces definitive agreement to acquire Facet Biotech

Abbott and Facet Biotech Corporation announced today a definitive agreement for Abbott to acquire Facet, enhancing Abbott's early- and mid-stage pharmaceutical pipeline.

9 Mar 2010

Chimerix initiates CMX001 Phase 2 clinical trial in stem cell transplant patients for CMV

Chimerix, Inc., a biotechnology company developing orally-available antiviral therapeutics, today announced the initiation of a multi-center Phase 2 clinical trial designed to evaluate CMX001 in stem cell transplant recipients who are seropositive for cytomegalovirus (CMV).

9 Mar 2010

NASDAQ halts trading of InterMune's common stock, FDA PADAC to discuss pirfenidone NDA

InterMune, Inc. announced that NASDAQ has today halted trading of InterMune's common stock. The Pulmonary-Allergy Drugs Advisory Committee to the U.S. Food and Drug Administration meets today to review and discuss the company's New Drug Application for pirfenidone for the treatment of patients with idiopathic pulmonary fibrosis.

9 Mar 2010

Exelixis fourth-quarter revenues rise from $29.6M to $44.1M

Exelixis, Inc. today reported financial results for the fourth quarter and year ended December 31, 2009.

9 Mar 2010

Sartorius achieves operating earnings of 60.9M euros for 2009

Sartorius, a leading international laboratory and process equipment provider, increased its operating profit in 2009 despite the difficult macroeconomic climate and achieved operating earnings of 60.9 million euros, up from 56.8 million euros a year earlier. “As a result, we are among the companies that were able to close the 2009 year of crisis with a positive development of operating earnings,” commented CEO Dr. Joachim Kreuzburg on the company’s full-year results at the annual press conference in Goettingen, Germany.

From Sartorius 9 Mar 2010

PAF launches resource directory to assist underinsured consumers

Patient Advocate Foundation (PAF) – a national non-profit organization that seeks to safeguard patients through effective mediation assuring access to care, maintenance of employment and preservation of their financial stability relative to their diagnosis of life threatening or debilitating diseases – with the Patient Action Council Delegates, unveiled The National Underinsured Resource Directory, which is intended to help underinsured individuals and families locate important resources and seek alternative coverage options or methods to cover their healthcare needs.

9 Mar 2010

Growing human therapeutic proteins in algae can help reduce cancer treatment cost

Pharmaceutical companies could substantially reduce the expense of costly treatments for cancer and other diseases produced from mammalian or bacterial cells by growing these human therapeutic proteins in algae-rapidly growing aquatic plant cells that have recently gained attention for their ability to produce biofuels.

9 Mar 2010

Advaxis confirms long-term stability of its first clinical formulation of ADXS11-001

Advaxis, Inc., the live, attenuated Listeria monocytogenes (Listeria) immunotherapy company, has confirmed the long-term stability of its first clinical formulation of ADXS11-001, the Company’s lead immunotherapeutic.

9 Mar 2010

Restructuring results in reduction of Exelixis’ workforce by 40% and increases financial strength

Exelixis, Inc. today announced a restructuring as a consequence of its continued strategy to focus resources on the development of its key late-stage compounds. As its first priority, the company will aggressively advance XL184, XL147 and XL765, each of which is the subject of a large clinical development program.

9 Mar 2010

MDS ends strategic repositioning with divestiture of MDS Pharma Services Early Stage business

MDS Inc., a leading provider of products and services to the global health sciences markets, today announced that it has completed the divestiture of its MDS Pharma Services Early Stage business.

9 Mar 2010

ImmunoGen receives FDA orphan drug designation for IMGN901 compound in treatment of MCC

ImmunoGen, Inc., a biotechnology company that develops targeted anticancer products using its antibody expertise and Targeted Antibody Payload (TAP) technology, today announced that the US Food and Drug Administration (FDA) has granted orphan drug designation to its IMGN901 compound when used for the treatment of Merkel cell carcinoma (MCC). Through a separate process, the European Union (EU) Committee for Orphan Medicinal Products (COMP) concurrently also granted IMGN901 orphan medicinal product designation for the treatment of MCC.

8 Mar 2010

MabCure closes private placement, converts bridge loan into equity securities

MabCure, Inc., a biotechnology company using its proprietary technology to create highly specific monoclonal antibodies (MAbs) for the early detection of cancer, today announced that it has recently completed a private placement in the aggregate amount of $1 million. The amount is comprised of a $500,000 cash investment and the conversion of a $500,000 bridge loan that was made in September 2009, into equity securities.

8 Mar 2010

NOVAVAX' Stage B 2009 H1N1 VLP pandemic influenza vaccine study in Mexico: Enrollment complete

Novavax, Inc. announced today that the enrollment of over 3,500 subjects in Mexico has been completed in Stage B of its pivotal 2009 H1N1 virus-like-particle (VLP) pandemic influenza vaccine study. With the 1,000 subjects already enrolled in Stage A of the trial, the enrollment in this pivotal trial is now complete with over 4,500 subjects.

8 Mar 2010

Likvor receives first order for Likvor CELDA system from Aalborg Hospital, North Denmark Region

LinkMed’s portfolio company Likvor has received its first order for the Likvor CELDA™ system from a customer outside Sweden. The order comes from Aalborg Hospital which is the largest hospital in the North Denmark Region.

8 Mar 2010

Sigma Life Science extends portfolio of knockout rat models with the release of ADME/Tox applications

Sigma® Life Science, an innovative brand of Sigma-Aldrich®, today extended its portfolio of knockout rat models with the announcement of a new suite of models designed to facilitate more predictive absorption, distribution, metabolism, excretion and toxicity (ADME/Tox) studies.

8 Mar 2010

Inability to motivate diabetics with poor control to overcome barriers inhibiting healthier lifestyles frustrates physicians

Diabetes affects approximately 8 percent of the people in the United States and adults with diabetes have heart disease death rates two to four times higher than adults without diabetes, according to the American Diabetes Association. A new study shows that primary care physicians believe the barriers that put patients with uncontrolled diabetes at risk for cardiovascular disease as being patient-related or system-related.

6 Mar 2010

Senesco insiders elect to convert common stock formerly held by Stanford Venture Capital at $0.83

Senesco Technologies, Inc. reported today that the insiders of the Company who had previously purchased all of the convertible debentures, warrants and common stock of Senesco which were formerly held by Stanford Venture Capital Holdings, Inc. have elected, subject to shareholder approval, to convert the convertible debentures at a conversion price of $0.83.

6 Mar 2010

University of Delaware psychology student wins NIH Ruth L. Kirschstein National Research Service Award

Amber J. Belcher, a doctoral student in psychology at the University of Delaware, has won the Ruth L. Kirschstein National Research Service Award from the National Institutes of Health (NIH). The fellowship will support Belcher's research on how couples cope with breast cancer.

6 Mar 2010

PPA: Assistance programs for uninsured and financially struggling patients

An article in the Times Courier recently highlighted the Partnership for Prescription Assistance (PPA), a group that has helped more than 6 million uninsured and financially struggling patients find assistance programs that provide the medicines they need for free or nearly free.

6 Mar 2010

Biotechnology News and Research

FDA's Advisory Committee votes 9-3 to recommend approval of Esbriet for treatment of patients with IPF

Abbott announces definitive agreement to acquire Facet Biotech

Chimerix initiates CMX001 Phase 2 clinical trial in stem cell transplant patients for CMV

NASDAQ halts trading of InterMune's common stock, FDA PADAC to discuss pirfenidone NDA

Exelixis fourth-quarter revenues rise from $29.6M to $44.1M

Sartorius achieves operating earnings of 60.9M euros for 2009

PAF launches resource directory to assist underinsured consumers

Growing human therapeutic proteins in algae can help reduce cancer treatment cost

Advaxis confirms long-term stability of its first clinical formulation of ADXS11-001

Restructuring results in reduction of Exelixis’ workforce by 40% and increases financial strength

MDS ends strategic repositioning with divestiture of MDS Pharma Services Early Stage business

ImmunoGen receives FDA orphan drug designation for IMGN901 compound in treatment of MCC

MabCure closes private placement, converts bridge loan into equity securities

NOVAVAX' Stage B 2009 H1N1 VLP pandemic influenza vaccine study in Mexico: Enrollment complete

Likvor receives first order for Likvor CELDA system from Aalborg Hospital, North Denmark Region

Sigma Life Science extends portfolio of knockout rat models with the release of ADME/Tox applications

Inability to motivate diabetics with poor control to overcome barriers inhibiting healthier lifestyles frustrates physicians

Senesco insiders elect to convert common stock formerly held by Stanford Venture Capital at $0.83

University of Delaware psychology student wins NIH Ruth L. Kirschstein National Research Service Award

PPA: Assistance programs for uninsured and financially struggling patients

Event guide: 3rd IMPACCT Real World Evidence Summit Europe eBook

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo

Latest News